Clinical trials: Advanced Solid Malignant Tumor
Solid Tumor
A Clinical Study of the Safety and Effectiveness of an Investigational Cell Therapy Given With and Without an Investigational RNA-based Vaccine in Patients With Organ Tumors
This is a Phase I, FIH, open-label, multi-site, dose escalation trial with expansion cohorts to evaluate safety and preliminary efficacy of claudin 6 (CLDN6) chimeric antigen receptor T cells (CAR-T) with or without CLDN6…
- Trial name
- NCT04503278
- Testing
- CLDN6 CAR-T, CLDN6 uRNA-LPX/CLDN6 modRNA-LPX
- Where
- 12 sites in Australia, Germany and 2 more
- Volunteers
- 214 people
- Sponsor
- BioNTech Cell & Gene Therapies GmbH
Advanced Cancer
An Investigational Immunotherapy Study of BMS-986258 Alone and in Combination With Nivolumab in Participants With Solid Cancers That Are Advanced or Have Spread
The purpose of this study is to determine whether BMS-986258 both monotherapy and in combination with Nivolumab is safe and tolerable in the treatment of advanced malignant tumors.
- Trial name
- NCT03446040
- Testing
- BMS-986258, Nivolumab, rHuPH20
- Where
- 16 sites in United States, Australia and 2 more
- Volunteers
- 92 people
- Sponsor
- Bristol-Myers Squibb
Advanced Cancer
C14 Study in Oncology Patients With Advanced and/or Metastatic Solid Tumors
This is an open-label study being conducted to determine the metabolism and physiological disposition of radiolabeled LY2603618 after a single dose in patients with advanced and/or metastatic solid tumors.
- Trial name
- NCT01296568
- Testing
- LY2603618, Pemetrexed, Gemcitabine
- Where
- Switzerland
- Volunteers
- 3 people
- Sponsor
- Eli Lilly and Company
Solid Tumor, Adult
Safety, Tolerability, and Pharmacokinetics of EVT801 in Patients With Advanced Solid Tumours
The main purpose of this study is to evaluate the safety and tolerability of EVT801 in subjects with advanced or metastatic solid tumours.
- Trial name
- NCT05114668
- Testing
- EVT801
- Where
- 2 sites in France
- Volunteers
- 32 people
- Sponsor
- Kazia Therapeutics Limited
Bladder Cancer, Gastric Cancer
Phase 1/2 Study of APR-246 in Combination With Pembrolizumab in Subjects With Solid Tumor Malignancies
A phase 1/2, open-label, study to determine the safety and preliminary efficacy of APR-246 in combination with pembrolizumab in subjects with solid tumor malignancies.
- Conditions
- Bladder Cancer, Gastric Cancer, Non Small Cell Lung Cancer, NSCLC
- Trial name
- NCT04383938
- Testing
- APR-246 (eprenetapopt) + Pembrolizumab
- Where
- 8 sites in United States
- Volunteers
- 40 people
- Sponsor
- Aprea Therapeutics
Advanced Solid Tumor
TR128 in Patients With Advanced Solid Tumors
This is a open-label, 3+3 design, dose escalation and expansion, phase I study, to evaluate the safety and tolerability, and to determine the Recommended Phase II Dose (RP2D) of TR128 when administered qd in patients with…
- Trial name
- NCT05751356
- Testing
- TR128
- Where
- 3 sites in China
- Volunteers
- 50 people
- Sponsor
- Tarapeutics Science Inc.
Advanced Solid Tumor, Metastatic Colorectal Carcinoma
A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours
This is a first-in-human, Phase 1, non-randomized, multicenter, open-label clinical study designed to investigate the safety, tolerability, dosimetry, biodistribution, and pharmacokinetics (PK) of [225Ac]-FPI-2068…
- Conditions
- Advanced Solid Tumor, Metastatic Colorectal Carcinoma, Head and Neck Squamous Cell Carcinoma, Non-small Cell Lung Cancer
- Trial name
- NCT06147037
- Testing
- FPI-2053, [111In]-FPI-2107, [225Ac]-FPI-2068
- Where
- 8 sites in United States, Canada
- Volunteers
- 13 people
- Sponsor
- AstraZeneca
Advanced Solid Tumor, Non Small Cell Lung Cancer Metastatic
Study to Investigate DRP-104 in Adults With Advanced Solid Tumors
The purpose of this study is to characterize the safety, tolerability, pharmacokinetics, pharmaco-dynamics and preliminary anti-tumor activity of DRP-104 (sirpiglenastat) administered via intravenous infusion or via subcutaneous…
- Trial name
- NCT04471415
- Testing
- DRP-104, atezolizumab
- Where
- 22 sites in United States, Germany and 3 more
- Volunteers
- 61 people
- Sponsor
- Dracen Pharmaceuticals, Inc.
Solid Tumor
A Study to Evaluate Safety, Tolerability, PK/PD and Preliminary Efficacy of HBM4003 Combined With Anti-PD-1 Antibody
This is an open-label, multi-center phase 1 study. The trial, consisting of Part 1a dose confirmation and Part 1b dose expansion, is designed to evaluate the safety, tolerability, PK/PD and preliminary efficacy of HBM4003 in…
- Trial name
- NCT04866485
- Testing
- HBM4003 and pembrolizumab
- Volunteers
- 66 people
- Sponsor
- Harbour BioMed (Guangzhou) Co. Ltd.
Locally Advanced or Metastatic Solid Tumor
A Study of Rebastinib (DCC-2036) in Combination With Carboplatin in Patients With Advanced or Metastatic Solid Tumors
This is an open-label Phase 1b/2 multicenter study of rebastinib (DCC-2036) in combination with carboplatin designed to evaluate the safety, tolerability, and pharmacokinetics (PK) in participants with advanced or metastatic…
- Trial name
- NCT03717415
- Testing
- Rebastinib, Carboplatin
- Where
- 9 sites in United States
- Volunteers
- 70 people
- Sponsor
- Deciphera Pharmaceuticals, LLC
Tumor, Tumor, Solid
Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1)
A Phase 2 multi-center open-label basket trial of nab-sirolimus for adult and adolescent patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes
- Conditions
- Tumor, Tumor, Solid, Metastasis, Metastatic Cancer
- Trial name
- NCT05103358
- Testing
- nab-sirolimus
- Where
- 166 sites in United States, Puerto Rico and 1 more
- Volunteers
- 128 people
- Sponsor
- Aadi Bioscience, Inc.
Neoplasms
[177Lu]-NeoB in Patients With Advanced Solid Tumors and With [68Ga]-neoB Lesion Uptake
First in Human (FIH) study to characterize the safety, tolerability, pharmacokinetics (PK), distribution, radiation dosimetry, and anti-tumor activity of [177Lu]-NeoB in patients with advanced solid tumors known to overexpress…
- Trial name
- NeoRay (NCT03872778)
- Testing
- [177Lu]-NeoB, [68Ga]-NeoB, LCZ696
- Where
- 11 sites in United States, Austria and 4 more
- Volunteers
- 35 people
- Sponsor
- Advanced Accelerator Applications
Breast Cancer, Solid Tumor
A Study of GNC-035, a Tetra-specific Antibody, in Participants With Locally Advanced or Metastatic Solid Tumors
In this study, the safety, tolerability and preliminary effectiveness of GNC-035 in participants with locally advanced or metastatic solid tumors will be investigated to assess the dose-limiting toxicity (DLT), maximum tolerated…
- Trial name
- NCT05039931
- Testing
- GNC-035
- Where
- China
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Gastrointestinal Tumor, Solid Tumor
A Study of SI-B036 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumors and Other Solid Tumors
This study is an open-label, multicenter, non-randomized Phase I clinical study with dose-escalation and expansion cohorts, designed to evaluate the safety, tolerability, pharmacokinetic characteristics, and preliminary efficacy…
- Trial name
- NCT07678970
- Testing
- SI-B036
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Carcinoma, Non-Small-Cell Lung, Mesothelioma
Pharmacokinetic, Safety, and Efficacy Effects of Oral LBH589 on Dextromethorphan in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer or Malignant Pleural Mesothelioma
This study will investigate the effect of oral LBH589 on dextromethorphan, a CYP2D6 substrate, and to assess safety and efficacy of oral LBH589 when used with this co-medication in advanced stage NSCLC or malignant pleural…
- Trial name
- NCT00535951
- Testing
- LBH589
- Where
- 5 sites in United States, Canada
- Volunteers
- 18 people
- Sponsor
- Novartis Pharmaceuticals
Solid Tumor
Pharmacokinetic Study of SYP-0704A and Taxotere to Treat Patient With Advanced Solid Cancer
Primary Objective: Evaluation of the pharmacokinetic equivalence of two Docetaxel formulations in terms of AUC and Cmax.
- Trial name
- NCT01336582
- Testing
- taxotere
- Where
- South Korea
- Volunteers
- 42 people
- Sponsor
- Samyang Biopharmaceuticals Corporation
Solid Tumor
A Study of WX390 Combined With Toripalimab in Patients With Advanced Solid Tumors
The goal of this clinical trial is to evaluate the safety and preliminary efficacy of WX390 combined with Toripalimab in patients with advanced solid tumors.
- Trial name
- NCT06117566
- Testing
- WX390, Toripalimab
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Shanghai Jiatan Pharmatech Co., Ltd
Advanced Solid Cancers
Phase II/III Trial of PRL3-Zumab in Advanced Solid Tumor Patients
This is a Multi-Center, Phase II/III, open-label, single dose level (6 mg/kg) basket trial of PRL3-zumab monotherapy in solid cancer patients.
- Trial name
- PRL3-zumab (NCT07290088)
- Testing
- PRL3-ZUMAB
- Where
- 4 sites in Malaysia
- Volunteers
- 52 people
- Sponsor
- Intra-IMMUSG Pte Ltd
Advanced Solid Tumor
A Study of the ILB-3101 in Patients with Advanced Solid Tumors
ILB-3101 is a fully humanized IgG1 antibody-drug conjugate (ADC) which specifically binds to B7-H3, a target wildly expressed on solid tumor cells.
- Trial name
- NCT06426680
- Testing
- ILB-3101
- Where
- China
- Volunteers
- 240 people
- Sponsor
- Innolake Biopharm
Malignant Solid Tumor
A Trial of AVID200, a Transforming Growth Factor β (TGFβ) Inhibitor, in Patients Malignancies
TGFβ has profound local immunosuppressive and immunoexclusion effects in the tumor microenvironment that are integrally involved in the failure of immune checkpoint inhibitors in some tumors.
- Trial name
- NCT03834662
- Testing
- AVID200
- Where
- 3 sites in United States, Canada
- Volunteers
- 19 people
- Sponsor
- Bristol-Myers Squibb
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.